Immune Design is a privately-held clinical-stage biotechnology company headquartered in Seattle, WA with offices in San Francisco, CA. Immune Design brings together some of the world's leaders in the field of molecular immunology to develop two synergistic platforms of next-generation vaccines designed to treat cancer, infectious diseases, allergy, and autoimmune disorders. The company employs leading-edge technologies that target dendritic cells for more precise activation of the immune response. These include DCVex™, a novel lentiviral vector platform engineered to deliver antigen-encoding nucleic acids directly to dendritic cells in vivo, and GLAAS™, a TLR4 agonist platform that activates dendritic cells by up-regulating key molecules for efficient antigen presentation and produces Th1 cytokines to enhance the immune response.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/30/13 | $49,000,000 | Series C |
Alta Partners Osage Venture Partners Sanofi-Genzyme BioVentures The Column Group Topspin Fund Versant Ventures | undisclosed |
